Terms of Use

Welcome to Apertura. Please read the following terms and conditions of use (the “Terms of Use”) carefully before using this Website. Your use of this Website is subject to, and constitutes acceptance of, the terms and conditions included in these Terms of Use.

GENERAL
This website at www.aperturagtx.com and its subdomains (this “Website”) is provided by Apertura Gene Therapy (“Apertura”, “we”, “us”, “our”) for the convenience of visitors to our Website. Nothing on this Website should be construed as an offer to form a binding contract, as a grant of any license or as a transfer of any intellectual property. Your use of this Website is at your own risk. Notwithstanding any other provision herein, Apertura reserves the right, in the event of a violation of these Terms of Use, to protect its rights, property and interests to the maximum extent permitted by law.

FORWARD-LOOKING STATEMENTS
This Website may contain forward-looking statements about Apertura’s financial and operating performance and business plans, technological capabilities, and opportunities currently in development that involve substantial risks and uncertainties. Actual results could differ materially from the expectations and projections set forth in those statements. Apertura assumes no obligation to update any forward-looking statements as a result of new information, changed circumstances or future events, or for any other reasons.

COPYRIGHTS AND TRADEMARKS
This Website, and the information which it contains, including its content, organization, graphics, design, compilation and other item appearing herein, is the property of Apertura and its affiliates and licensors and is protected from unauthorized copying and dissemination by United States copyright law, international conventions and other intellectual property laws. All trademarks and logos appearing on this Website are the property of their respective owners. Nothing on this Website should be construed to grant any license or right in or to any trademarks, logos or other intellectual property rights. All rights are reserved by the owners of each trademark, service mark, logo or other intellectual property, except as otherwise described in these Terms of Use.

PRIVACY
At Apertura, we strive to make your use of this Website safe and secure. Accordingly, your use of this Website, and any information (including, without limitation, personal information) you submit to Apertura through or in connection with this Website, is subject to Apertura’s Privacy Policy, which is available here. Our Privacy Policy is hereby incorporated by reference into these Terms of Use. The sender of any information to Apertura is solely responsible for its content, including, without limitation, its accuracy, truthfulness and non-infringement of any other person’s legal rights.

RULES OF CONDUCT
In connection with you use of this Website, you may not:

Use the Website for any purpose that is fraudulent or otherwise tortious or unlawful.
Interfere with or disrupt the operation of the Website or the servers or networks used to make the Website available, including by hacking or defacing any portion of the Website; or violate any requirement, procedure or policy of such servers or networks.
Reproduce, modify, adapt, translate, create derivative works of, sell, rent, lease, loan, timeshare, distribute or otherwise exploit any portion of (or any use of) the Website except as expressly authorized herein, without our express prior written consent.
Frame or mirror any portion of the Website, or otherwise incorporate any portion of the Website into any product or service, without our express prior written consent.
Use any robot, spider, site search/retrieval application or other manual or automatic device to retrieve, index, “scrape,” “data mine” or otherwise gather information from the Website, or reproduce or circumvent the navigational structure or presentation of the Website, without our express prior written consent. Notwithstanding the foregoing, and subject to compliance with any instructions posted in the robots.txt file located in the Website’s root directory, we grant to the operators of public search engines permission to use spiders to copy materials from the Website for the sole purpose of (and solely to the extent necessary for) creating publicly available, searchable indices of such materials, but not caches or archives of such materials. We reserve the right to revoke such permission either generally or in specific cases, at any time and without notice.
You will not use the Website for any purposes that is unlawful or prohibited by the Terms of Use. You are responsible for obtaining, maintaining and paying for all hardware and all telecommunications and other services needed to use the Website.

SUBMITTED MATERIALS
Unless specifically requested, Apertura does not solicit, nor does Apertura wish to receive, any confidential, secret or proprietary information or other material from you through this Website, by e-mail, or in any other way. Any materials submitted or sent on or through this Website in any manner (collectively, “Submitted Materials”) will be deemed to not be confidential or secret and maybe used by us in any manner consistent with these Terms of Use and our Privacy Policy. By submitting Submitted Materials on this website, you: (i) represent and warrant that you either own your Submitted Materials, or that you have the necessary licenses, rights, consents and permissions to use such Submitted Materials and submit them to this website; and (ii) you grant Apertura a royalty-free, unrestricted, worldwide, perpetual, irrevocable, non-exclusive and fully transferable, assignable and sublicensable right and license to use such material (in whole or part) in any manner and/or to incorporate it (in whole or in part) in other works (including, without limitation, this Website), products or services in any form, media, or technology now known or later developed. Apertura is not obligated to review any Submitted Materials. Apertura cannot be responsible for maintaining any Submitted Material you provide to this website, and we may delete or destroy any such Submitted Material at any time.

LINKS TO OTHER WEBSITES
This Website may contain links to websites maintained by other companies who are not affiliated with Apertura. Apertura is providing these links to you only as a convenience. The inclusion of any link does not imply that Apertura endorses any third-party website or third-party company or product. Apertura does not have any control over the content of such third-party websites and assumes no responsibility whatsoever for the functionality of such websites or for the accuracy of any information presented at such other websites.

NO WARRANTIES
THIS WEBSITE AND OTHER INFORMATION ON OR ACCESSIBLE FROM THIS WEBSITE ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT. SPECIFICALLY, BUT WITHOUT LIMITATION, APERTURA DOES NOT WARRANT THAT: (i) THE INFORMATION AVAILABLE THROUGH THIS WEBSITE IS FREE OF ERRORS; (ii) THE CONTENT, FUNCTIONS OR SERVICES PROVIDED BY THIS WEBSITE WILL BE UNINTERRUPTED, SECURE OR FREE OF BUGS, ERRORS. PROBLEMS OR OTHER LIMITATIONS; (iii) DEFECTS WILL BE CORRECTED; OR (iv) THIS WEBSITE OR THE SERVER(S) THAT MAKE IT AVAILABLE ARE FREE OF VIRUSES OR OTHER HARMFUL COMPONENTS.
APERTURA AND ITS AFFILIATES AND LICENSORS CANNOT AND DO NOT GUARANTEE THAT ANY PERSONAL INFORMATION SUPPLIED BY YOU WILL NOT BE MISAPPROPRIATED, INTERCEPTED, DELETED, DESTROYED OR USED BY OTHERS.

DISCLAIMER
IN NO EVENT SHALL APERTURA BE LIABLE TO YOU, ANY OTHER USER OF THIS WEBSITE, THIRD-PARTY PROVIDERS OR ANY OTHER PERSON OR ENTITY FOR ANY SPECIAL, INCIDENTAL, PUNITIVE, CONSEQUENTIAL, EXEMPLARY OR OTHER INDIRECT DAMAGES (INCLUDING WITHOUT LIMITATION DAMAGES FOR LOSS OF PROFITS, LOSS OF DATA, LOSS OF USE OR COSTS OF OBTAINING SUBSTITUTE GOODS OR SERVICES) ARISING OUT OF THE USE, INABILITY TO USE, UNAUTHORIZED ACCESS TO OR USE OR MISUSE OF THIS WEBSITE, WHETHER BASED UPON WARRANTY, CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE, EVEN IF WE HAVE BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES OR LOSSES.

EXCLUSIONS
SOME JURISDICTIONS DO NOT ALLOW THE EXCLUSION OF CERTAIN WARRANTIES OR THE LIMITATION OR EXCLUSION OF LIABILITY FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES. ACCORDINGLY, SOME OF THE ABOVE LIMITATIONS MAY NOT APPLY TO YOU.

NO SOLICITATION OR INVESTMENT ADVICE
Nothing on this Website constitutes or forms a part of any offer for sale or subscription of, or any invitation to offer to buy or subscribe for, any securities, nor should it or any part of it form the basis of or be relied upon in connection with any contract or commitment whatsoever. Nothing here in is intended to constitute legal, accounting, tax, securities or investment advice, an opinion regarding the appropriateness of any investment, or an offer or a solicitation to buy or sell a security of any type or to engage in any other transaction. The contents of this website are intended for general information purposes only.

GOVERNING LAW
This Website can be accessed from every U.S. state, as well as from other countries around the world. Each of those places has laws that may differ from those of the State of New York, where Apertura’s corporate office is located. By accessing this Website, you agree that the laws of the State of New York, without regard to its conflicts of laws principles, will apply to all disputes based on, arising out of or relating to your use of this Website or any information it contains. With respect to such disputes, you also agree and hereby submit to the exclusive personal jurisdiction and venue of any state or federal court located in New York, New York.

ARBITRATION
Any and all controversies, disputes, demands, counts, claims, or causes of action (including the interpretation and scope of this clause, and the arbitrability of the controversy, dispute, demand, count, claim, or cause of action) between you and us or our successors or assigns shall exclusively be settled through binding and confidential arbitration.

Arbitration shall be subject to the Federal Arbitration Act and not any state arbitration law. Unless otherwise agreed upon by the parties in writing, the arbitration will be conducted before one arbitrator and will be governed by the American Arbitration Association’s (“AAA”) Commercial Arbitration Rules and, if the arbitrator deems them applicable, the Supplementary Procedures for Consumer Related Disputes (collectively, the “Rules and Procedures”).

To the fullest extent permitted by applicable law, you and we must abide by the following rules: (1) ANY CLAIMS BROUGHT BY YOU OR US MUST BE BROUGHT IN THE PARTY’S INDIVIDUAL CAPACITY, AND NOT AS A PLAINTIFF OR CLASS MEMBER IN ANY PURPORTED CLASS OR REPRESENTATIVE PROCEEDING; (2) THE ARBITRATOR MAY NOT CONSOLIDATE MORE THAN ONE PERSON’S CLAIMS, MAY NOT OTHERWISE PRESIDE OVER ANY FORM OF A REPRESENTATIVE OR CLASS PROCEEDING, AND MAY NOT AWARD CLASS-WIDE RELIEF; (3) the arbitration shall be confidential, and neither you nor we may disclose the existence, content or results of any arbitration, except as may be required by law or for purposes of enforcement of the arbitration award; (4) the arbitrator may award any individual relief or individual remedies that are permitted by applicable law; and (5) each side pays its own attorneys’ fees and expenses unless there is a statutory provision that requires the prevailing party to be paid its fees and litigation expenses, and, in such instance, the fees and costs awarded shall be determined by the applicable law.

SEVERABILITY
If any provision of these Terms of Use shall be unlawful, void or for any reason unenforceable, then that provision shall be deemed severable from the Terms of Use and shall not affect the validity and enforceability of any remaining provisions. Our failure to enforce any provision of these Terms of Use shall not be deemed a waiver of such provision nor the right to enforce such provision.

MISCELLANEOUS
You may not assign or transfer your rights or obligations under these Terms of Use in whole or in part to any third party without our consent. These Terms of Use shall bind and inure to the benefit of the parties to these Terms of Use and their respective successors and permitted assigns. We and you are independent contractors and are not partners, joint venturers, agents, employees or representatives of the other party. These Terms of Use contain the entire understanding of the parties with respect to the transactions and matters contemplated herein, supersede all previous communications, understandings and agreements (whether oral or written) other than any click-through or end user license agreement provided by us, and cannot be amended except by a writing signed by both parties or by our posting of an amended version of these Terms of Use on this Website. The headings and captions used in these Terms of Use are used for convenience only and are not to be considered in construing or interpreting these Terms of Use. If any part of these Terms of Use is held to be unlawful, void or unenforceable, that part shall be deemed severable and shall not affect the validity and enforceability of the remaining provisions.

CHANGES TO THIS TERMS OF USE
Apertura reserves the right to change these Terms of Use from time to time for any reason without notice. Any such changes shall be effected by posting of the updated Terms of Use to this Website; provided that any such changes shall only apply to your use of this Website after the date of such change(s), unless you expressly accept retroactive application of such change(s) via a click-through agreement, a signed agreement or otherwise.

For Additional Information
If you have any questions about these Terms of Use, please contact us at:

Apertura
345 Park Avenue South
New York, NY 10010
Email: info@aperturagtx.com

In order to make this Privacy Notice reasonably accessible to users with disabilities, we follow the Web Content Accessibility Guidelines (WCAG 2.1). Users with disabilities may access the Website, including this Privacy Policy, using standing navigation on the website through the aid of additional software, such as screen readers.

Scroll to Top

Andrew Steinsapir

Acting Chief Technology Officer

Andrew Steinsapir is the Acting Chief Technology Officer of Apertura Gene Therapy and a Director, Gene Therapy Program Lead of Deerfield Management’s Discovery and Development team. Prior to joining Deerfield in 2021, Mr. Steinsapir was a Consultant for over three years at Dark Horse Consulting Group, where he provided strategic and tactical support for more than 30 cell and gene therapy firms, pharma, and investment firms. Previous to Dark Horse, Mr. Steinsapir worked at 4D Molecular Therapeutics for over three years, holding various positions, with his most recent role being Senior Process Development Associate I. Mr. Steinsapir holds a BS in Chemical Engineering with an emphasis on Biotechnology from the University of California, Berkeley.

Juliana Leung, PhD

The Broad Institute

Juliana Leung, PhD, is the Senior Director of Business Development and Licensing Transactions at the Broad Institute of MIT and Harvard, where she leads Broad’s business development and licensing team. She has more than 15 years of business development and transactional experience. Juliana provides expertise to build collaborations with industry as well as partnerships with pharma, biotech, and venture groups that are eager to translate technologies into products that can benefit patients, the research community, and improve human health.

Before joining the Broad in 2012, Juliana was Senior Business Strategy and Licensing Manager for Research Ventures and Licensing at Partners Healthcare, now referred to as Innovation at MassGeneral Brigham. She received her SB in Biology from MIT and her PhD in Cellular, Molecular and Biophysical Studies from Columbia University in New York.

Ben Deverman, PhD

Senior Director of Vector Engineering at the Broad Institute of MIT and Harvard

Ben Deverman is the Senior Director of Vector Engineering and an Institute Scientist at the Broad Institute of MIT and Harvard. Ben’s laboratory in the Stanley Center for Psychiatric Research at the Broad Institute develops and applies novel high-throughput screens and data-driven protein and genome engineering techniques to create more efficient and targeted AAV vectors to advance gene therapy and support scientific discovery. In prior work at the California Institute of Technology, Ben and colleagues identified numerous capsids, including AAV-PHP.B and an enhanced variant, AAV-PHP.eB, that made efficient brain-wide gene delivery possible for the first time. Ben earned a PhD in Molecular Cell Biology from Washington University and was trained as a postdoc in neuroscience at the California Institute of Technology.

Michael Greenberg, PhD

Chair of the Department of Neurobiology and the Nathan Marsh Pusey Professor of Neurobiology at Harvard Medical School

Dr. Greenberg received his PhD from The Rockefeller University in 1982 and carried out his postdoctoral research at New York University Medical Center. After joining the faculty at Harvard Medical School in 1986, Dr. Greenberg served first as the founding Director of the F.M. Kirby Neurobiology Center at Boston Children’s Hospital and since 2008 as Chair of the Department of Neurobiology at Harvard Medical School.

Joseph La Barge

Apertura Gene Therapy

Joseph La Barge is CEO and serves on the Board of Managers of Apertura Gene Therapy. Previously, Mr. La Barge was an executive at Spark Therapeutics, Inc., serving as Chief Business Officer from 2019 to 2021 and as Chief Legal Officer from 2013 to 2019. In these roles, he oversaw many areas of company growth, including business development, patient advocacy, quality assurance, legal affairs, compliance, finance, public policy and global pricing and reimbursement, growing the company to 830 employees over eight years. He led the negotiation of Spark’s acquisition by Roche, raised more than $1 billion in capital from private and public financings and oversaw the in-license of numerous product candidates and platform technologies. Mr. La Barge also managed the acquisition and construction of Spark’s initial 180,000 square feet office and laboratory space, including GMP suites, to manufacture the global supply of Luxturna. Prior to Spark, Mr. La Barge served as Vice President, General Counsel & Secretary, Chief Compliance Officer at Tengion, Inc., where he was responsible for managing legal affairs, compliance and quality assurance. Mr. La Barge has served as a Member of the American Society of Gene & Cell Therapy Government Affairs Committee. He earned his BA in Education and Psychology at Bucknell University and his JD at Temple University James E. Beasley School of Law.

David Greenwald, PhD

Deerfield Management Company

Dave serves on the Board of Managers of Apertura Gene Therapy.

Dr. Greenwald was a Howard Hughes Medical Institute research fellow while earning a BS in Cellular Biology and Molecular Genetics from the University of Maryland, College Park and earned his PhD in Genetics from Tufts University. Dr. Greenwald currently serves on the Boards of Jaguar Gene Therapy, Axovia Therapeutics, and Apertura Gene Therapy, and has worked at Deerfield Management since 2018.

Elise Wang

Deerfield Management Company

Ms. Wang is a Partner and Head of Private Equity Capital Markets on the Public Structured Finance team at Deerfield Management and joined the Firm in 2010. Ms. Wang provides extensive research and analysis on individual companies operating in the healthcare industry in both the US and Europe.

Ms. Wang is a board member of Jaguar Gene Therapy. Prior to Deerfield, Ms. Wang was a Senior Research Analyst and Managing Director covering the biotechnology sector at PaineWebber and Citigroup. She began her career in healthcare as a venture capitalist and banker at PaineWebber and was an officer of PaineWebber Development Corporation, which managed nearly $1 billion in assets representing three PaineWebber funds and several research and development limited partnerships (RDLPs) invested in biotechnology and high technology companies.

Ms. Wang holds an AB in Engineering Sciences with a specialty in Biomechanics from Harvard University and an MBA from Harvard Business School.

Jonathan Leff

Deerfield Management Company

Mr. Leff is a Partner on the Therapeutics team at Deerfield Management since 2013 and Chairman of the Deerfield Institute. He focuses on venture capital and structured investments in biotechnology and pharmaceuticals. Prior to Deerfield, for more than sixteen years, Mr. Leff was with Warburg Pincus, where he led the firm’s investment efforts in biotechnology and pharmaceuticals. He is a member of the Boards of several private healthcare companies as well as several not-for-profit Boards, including the Spinal Muscular Atrophy Foundation, Friends of Cancer Research, Reagan-Udall Foundation for the Food and Drug Administration and the Columbia University Medical Center Board of Advisors. Mr. Leff has also been active in public policy discussions related to healthcare and medical innovation. He previously served as a member of the Executive Committee of the Board of the National Venture Capital Association (NVCA), where he led NVCA’s life sciences industry efforts as Chair of NVCA’s Medical Innovation and Competitiveness Coalition (NVCA-MedIC), and also previously served on the Board of the Biotechnology Innovation Organization. Mr. Leff holds an AB from Harvard University and an MBA from Stanford University’s Graduate School of Business.

Roberto Pastrano

Vice President of Finance and Operations

Roberto Pastrano is Vice President of Finance and Operations at Apertura Gene Therapy. With over 17 years of Biotechnology and Pharmaceutical experience in finance, accounting, and operations, Mr. Pastrano oversees Apertura’s operations, IT, finance and accounting functions. Previously, Mr. Pastrano served as Senior Director and Corporate Controller at Day One Biopharmaceuticals, a biotechnology company focused on pediatric cancers, where he led the accounting, procurement, and IT functions. Prior to Day One, he spent six years at Loxo Oncology at Lilly, formerly Loxo Oncology, as Senior Director of Finance where he led the accounting, finance, procurement, and legal functions after joining the company as an Assistant Controller in August 2015. Notably, while at Loxo Oncology at Lilly, Mr. Pastrano played a key role in the development of Vitrakvi (larotrectinib), the second tissue agnostic FDA-approved drug for adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion & Retevmo (selpercatinib), the first FDA-approved therapy for patients with lung and thyroid cancers with RET gene alterations, which was approved under the FDA’s Accelerated Approval pathway with an orphan drug designation. Mr. Pastrano holds a BS in Accounting from the City University of New York – Herbert H. Lehman College and an MBA with a concentration in Finance.

Jordan Dubow, MD

Acting Chief Medical Officer

Dr. Jordan Dubow is the Acting Chief Medical Officer of Apertura Gene Therapy. Dr Dubow is a neurologist with fellowship training in movement disorders and vascular neurology and began his medial career in academia as a movement disorders and stroke neurologist. Dr. Dubow has extensive experience in the pharmaceutical and biotech industry, where he has served in full time and acting CMO capacities for both pubic and private companies, leading all clinical and regulatory aspects of development for small and large molecule drugs and cell and gene therapies. Dr. Dubow received his medical degree from the Northwestern University Feinberg School of Medicine. He completed his internal medicine internship, Neurology residency and fellowship training at University of California Los Angeles, Northwestern University and Weill Cornell Medical College.

Jenna Heyman

Head of Human Resources, Vice President

Jenna Heyman joined Apertura Gene Therapy as Vice President and Head of Human Resources, bringing more than a decade of experience in Human Resources, as well as exceptional knowledge of building strong high performing teams in the biotechnology and CDMO industry. In her previous role as Vice President of Human Resources at Recipharm, Ms. Heyman oversaw HR for Arranta Bio and Vibalogics, and was instrumental in helping execute a global growth strategy. There, she was responsible for all operational and strategic activity in HR, including the areas of talent acquisition and retention, benefits and compensation, employee development and growth and corporate culture. Prior, Ms. Heyman served in progressive leadership positions at Brammer Bio, which was acquired by Thermo Fisher Scientific. Ms. Heyman has a BA in Psychology and an MA in Education from Quinnipiac University. She also holds a SHRM-SCP (Society of HR Management – Senior Certified Professional) certification.

Diego Garzón, PhD

Vice President of Corporate Development

Dr. Diego Garzón is Vice President of Corporate Development at Apertura Gene Therapy and has more than 16 years of biotechnology and pharmaceutical sector experience within the U.S. and internationally, with a background spanning commercial R&D and Business Development. Dr. Garzón brings extensive knowledge of multiple therapeutic areas and provides leadership in the areas of managing teams and portfolio execution, having previously brought seven medicines to the market. Prior to joining Apertura, Dr. Garzón held roles at Exicure, Allergan, BMS and Schering-Plough. He most recently served as Vice President, Corporate Development and Strategy at Exicure. Dr. Garzón received his BSc in Biology at the University of Waterloo, PhD in Neuroscience at McMaster University and MBA degrees from Queen’s University and Cornell University.

Sisi Chen, PhD

Senior Director of Platform Technology

Dr. Sisi Chen is  Senior Director of Platform Technology at Apertura Gene Therapy, where she and her teams are harnessing the power of machine learning and high-throughput experimentation to engineer better payloads and capsids for gene therapies. She brings over 15 years of research experience in technology development in the areas of functional and single-cell genomics, computational biology, and stem cell biology.Prior to Apertura, she served as the Director of the Beckman Single-cell Profiling and Engineering Center (SPEC) at Caltech, where she led a cross-functional computational and experimental team to leverage the power of single-cell genomics towards applications in therapeutic screening and cell engineering. Her work at SPEC on performing large-scale analyses of immune cell responses to small molecule drugs was awarded the Society of Laboratory Automation and Sciences (SLAS) 2021 Innovation Award. Dr. Chen earned a B.S. in Electrical engineering from MIT and a Ph.D. in Bioengineering from the University of California Berkeley.

Jorge Santiago-Ortiz, PhD

Senior Director of Chemistry, Manufacturing, and Controls (CMC)

Dr. Jorge Santiago-Ortiz is the Senior Director of Chemistry, Manufacturing, and Controls (CMC) at Apertura Gene Therapy. He is a chemical engineer with a background in bioprocess engineering, molecular biology, and biochemistry and a focus in gene therapy and process development. Born and raised in Puerto Rico, Jorge completed his bachelor’s degree in Chemical Engineering with a Biotechnology Certificate in 2010 at the University of Puerto Rico, Mayagüez; as an undergraduate student, he conducted research in biochemistry under Dr. Belinda Pastrana-Rios, where he worked on protein expression, purification, and characterization. In 2016, Jorge completed a Ph.D. in Chemical and Biomolecular Engineering with a minor in Molecular and Cell Biology at the University of California, Berkeley. Working in Dr. David Schaffer’s laboratory, his Ph.D. dissertation work focused on the engineering of lentiviral and adeno-associated virus (AAV) vectors for gene therapy applications using in vitro and in vivo directed evolution. Following the completion of his Ph.D., Jorge transitioned to an industry role at BioConsortia Inc. (Davis, CA), where he led the fermentation and scale-up of beneficial plant-associated microbes for enhanced crop yields and improved plant health. Prior to his current role at Apertura, Jorge worked as the Sr. Director of Process Development at BioCentriq, a gene and cell therapy contract development and manufacturing organization (CDMO) based in Newark, NJ, where he oversaw process development for gene and cell therapy clinical products and managed gene therapy projects. Jorge is an active member of the Society for Advancement of Chicanos/Hispanics & Native Americans in Science (SACNAS), and he also serves on the National Academies for Sciences, Engineering, and Medicine’s Standing Committee on Biotechnology Capabilities and National Security Needs and in the American Society of Gene and Cell Therapy’s Diversity, Equity, and Inclusion (DEI) Committee.

Apertura Benefits
Flexible Time Off
Medical, Dental, Vision
401K
Equity
And more!

David Tischler

Strategy & Operations Consultant

David Tischler is an Advisor to Apertura Gene Therapy leveraging a background focused on building and financing companies to commercialize life science innovations. Currently, he is engaged by venture capital firms and their therapeutics and bioengineering-focused portfolio companies to lead operations, business development, fundraising, and strategic commercialization projects. Most recently, David was the co-founder and CEO of ZetaGen Therapeutics, an early-stage life science company developing targeted local therapies for large unmet needs in the regenerative medicine and oncology markets. Prior to ZetaGen, David was a product manager at Castlight Health (NYSE: CSLT), where he helped launch Action, an artificial intelligence product that uses machine learning to manage the health of employee populations of Fortune 100 companies. David also served as acting CEO of DigiSight Technologies (now Verana Health), a venture-backed company that leverages large datasets to manage retinal diseases. Previously, served as the due diligence chair for Mass Medical Angels, a life science-focused angel investment group and also worked as an associate at Venzyme Venture Catalyst where he turned early-stage life science technologies from academic institutions into financeable companies. David has a BS in Biology from the University of Michigan and an MBA from the UC Berkeley-Haas School of Business.

Joseph La Barge

Chief Executive Officer

Joseph La Barge is CEO and serves on the Board of Managers of Apertura Gene Therapy. Previously, Mr. La Barge was an executive at Spark Therapeutics, Inc., serving as Chief Business Officer from 2019 to 2021 and as Chief Legal Officer from 2013 to 2019. In these roles, he oversaw many areas of company growth, including business development, patient advocacy, quality assurance, legal affairs, compliance, finance, public policy and global pricing and reimbursement, growing the company to 830 employees over eight years. He led the negotiation of Spark’s acquisition by Roche, raised more than $1 billion in capital from private and public financings and oversaw the in-license of numerous product candidates and platform technologies. Mr. La Barge also managed the acquisition and construction of Spark’s initial 180,000 square feet office and laboratory space, including GMP suites, to manufacture the global supply of Luxturna. Prior to Spark, Mr. La Barge served as Vice President, General Counsel & Secretary, Chief Compliance Officer at Tengion, Inc., where he was responsible for managing legal affairs, compliance and quality assurance. Mr. La Barge has served as a Member of the American Society of Gene & Cell Therapy Government Affairs Committee. He earned his BA in Education and Psychology at Bucknell University and his JD at Temple University James E. Beasley School of Law.